<DOC>
	<DOCNO>NCT01526070</DOCNO>
	<brief_summary>Over last several year , standard care wet macular degeneration become treatment intravitreal injection ranibizumab ( Lucentis , Genentech ) , administer frequently every 4 week . In contrast , clinical trial soluble VEGF receptor , Aflibercept/VEGF Trap-Eye ( Eylea , Regeneron Pharmaceuticals ) demonstrate maintained anatomic visual improvement many few injection ( typically monthly injection 3 month , follow every-other-month injection , 5 injection year ) . The purpose study determine whether patient switch ranibizumab VEGF Trap-Eye comparable result .</brief_summary>
	<brief_title>Study Bimonthly VEGF Trap-Eye Compared As-needed Administration Other Therapy Exudative Age-Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>1 . Patients old age 50 determine retinal physician Byers Eye Institute Stanford exudative AMD require treatment . 2 . Patients establish diagnosis exudative AMD maintain regimen intravitreal ranibizumab injection . 3 . Postmenopausal negative pregnancy test 4 . Patients establish diagnois exidative AMD switch intravitreal ranibizumab intravitreal VEGF TrapEYE . 1 . Patients previous concurrent history treatment retinal disease pharmacologic agent ranibizumab , include verteporfin photodynamic therapy , bevacizumab , triamcinolone , dexamethasone . 2 . Patients prior history vitrectomy surgery study eye . 3 . Patients enrol previous current clinical trial study medication AMD retinal vascular disease , include diabetic retinopathy retinal vein occlusion . 4 . Ocular medium opacity preclude proper retinal imaging 5 . Inadequate pupillary dilation achieve proper retinal imaging 6 . Concurrent use systemic antiVEGF agent 7 . CNV due cause , include histoplasmosis , uveitis , trauma , myopia 8 . Active recent ( &lt; 4 week ) recurrent inflammation eye 9 . Current vitreous hemorrhage study eye limit visualization fundus 10 . Active infectious conjunctivitis , keratitis , scleritis , endophthalmitis 11 . Untreated glaucoma IOP &gt; 25 eye 12 . Other ocular disease compromise visual acuity study eye amblyopia anterior ischemic optic neuropathy 13 . Pregnancy lactation 14 . History disease , exam finding , clinical laboratory contraindicates use drug 15 . Current treatment active systemic infection 16 . Evidence significant uncontrolled concomitant diseases cardiovascular disease , pulmonary , renal , hepatic , endocrine , GI disorder 17 . History recurrent significant infection bacterial infection 18 . Inability comply study followup procedure</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>